The part of the building designed by Frank O. Gehry at the Novartis AG campus at Basel in Switzerland.
Bloomberg | Getty Images
Swiss pharmaceutical giant Novartis On Friday, he reported in the fourth quarter about better than expected sales, but lacked his own leadership during a year -round part.
The net sales in the fourth quarter increased by 16% on a permanent currency to $ 13.2 billion, compared to $ 12.795 billion estimated by analysts estimated at the LSEG poll.
A quarterly adapted basic operational revenue was $ 4.86 billion compared to the expected $ 4.23 billion.
For 2024, net sales increased 12% on a permanent currency basis to $ 50.32 billion, compared to $ 50.47 billion. The year -round basic operational revenue increased by 22% to $ 19.5 billion compared to a prognosis of $ 17.02 billion.
In October, Novartis raised its guidelines for earnings from 2024 in October, saying that he expects a year -round net sale and a fundamental operational income to both grow for “high teenagers” compared to the previous “medium to high teens”.
This is the story of the news and will be updated soon.
